Angle says key biopsy product successfully used in melanoma analysis

Writer, Stock Market Wire
Tuesday, January 29, 2019 - 13:37

Liquid biopsy company Angle said a key product had been been successfully used to improve the workflows and sensitivity of lymph node analysis in melanoma.

The related research, led by Dr Bernhard Polzer at the Fraunhofer Institute for Toxicology and Experimental Medicine, was published in the International Journal of Cancer.

'This is another example of our leveraged approach with research customers delivering new applications for Parsortix,' chief executive Andrew Newland said.

'There is now the potential for the Parsortix system to be adopted as a standard approach for analysing lymph nodes, which is a requirement for all patients diagnosed with melanoma and several other cancer types.'

At 1:37pm: (LON:AGL) Angle PLC share price was +2.5p at 57.5p

Related content

Angle acquires outstanding shares in US subsidiary

Angle said Monday it had acquired the outstanding shares in its US operating subsidiary Angle North America after reaching agreement to acquire Dr Georgi Hvichia's...

Mon, 05/11/2018 - 08:27

Angle presents positive pre-natal testing study results in Massachusetts

Biopsy company Angle said it had gotten positive results from a pilot study of technology that harvests fetal cells from the peripheral blood of pregnant...

Mon, 29/10/2018 - 14:12

Angle's parsortix system shows evidence of circulating tumour cell clusters in glioblastoma

Liquid biopsy company Angle said Tuesday that its cell separation technology system was subject to a further peer-reviewed publication in the British Journal of Cancer....

Tue, 28/08/2018 - 10:08

Angle losses deepen on increased investment spend

Liquied biopsy company Angle posted a deeper annual loss, owing to planned investment in its offering.

Pre-tax losses for the year through April amounted...

Wed, 25/07/2018 - 14:50

Broker Forecast - finnCap issues a broker note on Angle PLC

finnCap today reaffirms its corporate investment rating on Angle PLC (LON:AGL) and raised its price target to 110p (from 108p).

Broker Forecasts data provided by...

Tue, 26/06/2018 - 08:10